Merck Announces TroFuse-005 Trial Evaluating Sacituzumab Tirumotecan (Sac-TMT) Met Primary Endpoints of Overall Survival (OS) and Progression-Free Survival (PFS) in Certain Patients With Advanced or R
Go back to Merck Announces TroFuse-005 Trial Evaluating Sacituzumab Tirumotecan (Sac-TMT) Met Primary Endpoints of Overall Survival (OS) and Progression-Free Survival (PFS) in Certain Patients With Advanced or R| Merck & Co. (NYSE: MRK) | Delayed: 115.48 +1.61 (1.41%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $113.87 | 52 Week High | $65.46 | |||
| Open | $113.97 | 52 Week Low | $47.97 | |||
| Day High | $115.63 | P/E | 78.56 | |||
| Day Low | $113.00 | EPS | $1.47 | |||
| Volume | 10,593,825 | |||||
